Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine

Leukemia Research

Volumn 37, Issue 6, 2013, Pages 609-613

  Adès, Lionel ^a   Sekeres, Mikkael A ^b   Wolfromm, Alice ^a   Teichman, Melissa L ^c   Tiu, Ramon V ^b   Itzykson, Raphael ^a   MacIejewski, Jaroslaw P ^b   Dreyfus, Francois ^a   List, Alan F ^c   Fenaux, Pierre ^a   Komrokji, Rami S ^c  

^a Groupe Francophone des Myelodysplasies   (France)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Azacitidine; CMML; Hypomethylating agent; Splenomegaly; Survival

Indexed keywords

AZACITIDINE; CYTARABINE; GROWTH FACTOR; HEMOGLOBIN; HYDROXYUREA;

ADULT; AGED; ARTICLE; BLAST CELL; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; COHORT ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEALTH PROGRAM; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLENOMEGALY; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BIOMARKERS, PHARMACOLOGICAL; FEMALE; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877084272     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.01.004     Document Type: Article

References (18)

1. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
2. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H., et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994, 87:746-754.
3. Germing U., Gattermann N., Minning H., Heyll A., Aul C. Problems in the classification of CMML - dysplastic versus proliferative type. Leuk Res 1998, 22:871-878.
4. Onida F., Kantarjian H.M., Smith T.L., Ball G., Keating M.J., Estey E.H., et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002, 99:840-849.
5. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
6. Aribi A., Borthakur G., Ravandi F., Shan J., Davisson J., Cortes J., et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007, 109:713-717.
7. Braun T., Itzykson R., Renneville A., de Renzis B., Dreyfus F., Laribi K., et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 2011, 118:3824-3831.
8. Costa R., Abdulhaq H., Haq B., Shadduck R.K., Latsko J., Zenati M., et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011, 117:2690-2696.
9. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109:52-57.
10. Wijermans P.W., Ruter B., Baer M.R., Slack J.L., Saba H.I., Lubbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 2008, 32:587-591.
11. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
12. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
13. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
14. Kulasekararaj A.G., Mohamedali A.M., Smith A.E., Lea N.C., Kizilors A., Abdallah A., et al. Polycomb complex group gene mutations and their prognostic relevance in 5-azacitidine treated myelodysplastic syndrome patients. ASH Annual Meeting Abstracts 2010, 125.
15. Wattel E., Guerci A., Hecquet B., Economopoulos T., Copplestone A., Mahe B., et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Blood 1996, 88:2480-2487.
16. Fianchi L., Criscuolo M., Breccia M., Maurillo L., Salvi F., Musto P., et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma 2012.
17. Thorpe M., Montalvão A., Pierdomenico F., Moita F., Almeida A. Treatment of chronic myelomonocytic leukemia with 5-azacitidine: a case series and literature review. Leuk Res 2012, 36:1071-1073.
18. Wong E., Seymour J.F., Kenealy M., Westerman D., Herbert K., Dickinson M. Treatment of chronic myelomonocytic leukemia with azacitidine. Leuk Lymphoma 2012, (October):3.